Physician profile
Christopher Price
NPI 1164426490
$11,808.52
in general payments reported to CMS, 2019-2025
48 companies · $932 in 2025
The $932 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $1,645 · 2021: $2,079 · 2022: $2,026 · 2023: $1,803 · 2024: $1,635 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.16 |
| Education | $204.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,683.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $926.45 | 2019-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $924.86 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $871.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.53 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $715.08 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $617.64 | 2019-2024 | Veozah |
| Novo Nordisk INC | $555.60 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $534.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $525.60 | 2019-2024 | |
| Allergan, INC. | $368.33 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $317.53 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.06 | 2019-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $214.25 | 2019-2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $192.53 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.